Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Visterra Strikes Deal With Pfizer, Presents Strong Data For Flu Drug

This article was originally published in The Pink Sheet Daily

Executive Summary

The start-up supplied few details about its arrangement with its Big Pharma partner, but receives cash as it prepares to take a promising influenza therapy into the clinic.

You may also be interested in...



Deals Of The Week: Merck/Simcere, Pfizer/Hisun, MedImmune/WuXi

The growing importance of emerging markets will be a primary discussion point Sept. 17-19 at Elsevier’s Pharmaceutical Strategic Alliances conference in New York

United Therapeutics Scores $45 Million To Develop Novel Virology Treatments

United Therapeutics Corp. gets a $45 million tranched grant from the U.S. National Institute of Allergy and Infectious Disease to develop broad-spectrum compounds against influenza and Dengue.

Craig Venter Wants To Extend Your Life (And Own Your Data)

The onetime Celera CEO says his new attempt to centralize biological information into a massive database could lead to breakthroughs that extend the human life span. Behind that bold goal is a more mundane data-licensing strategy that, although not splashy, could still improve medicine.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS074630

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel